Dabigatran versus warfarin in patients with mechanical heart valves - Wikidata - awgldk - TriplyDB

Dabigatran versus warfarin in patients with mechanical heart valves

Dabigatran versus warfarin in patients with mechanical heart valves

http://www.wikidata.org/entity/Q28297637

about

Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation Self-monitoring and self-management of oral anticoagulation Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy Review of the top 5 cardiology studies of 2013-14 Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence Dabigatran-Associated Intracranial Hemorrhage: Literature Review and Institutional Experience Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care Secondary stroke prevention: challenges and solutions Self-management of oral anticoagulation Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute Future prospects for contact factors as therapeutic targets Factor XI and contact activation as targets for antithrombotic therapy Anticoagulation for prosthetic valves 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.New Oral Anticoagulants in Nonvalvular Atrial Fibrillation Warfarin related nephropathy: a case report and review of the literature Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events Anticoagulation in atrial fibrillation Cardioembolic Stroke.Detecting nonvalvular atrial fibrillation and anticoagulant therapy in cardioembolic ischemic stroke.Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease.Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.[Therapy of aortic valve stenosis].Incidence and predictors of excessive warfarin anticoagulation in patients with atrial fibrillation-The EWA study.Anticoagulation for the acute management of ischemic stroke Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial Expanding use of new oral anticoagulants Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.Approach to the new oral anticoagulants in family practice: part 1: comparing the options.Sex differences in treatment quality of self-managed oral anticoagulant therapy: 6,900 patient-years of follow-up.Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives.Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting.Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012 Pregnancy complicated by valvular heart disease: an update.Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service--results from the prospective, multi-center, observational cohort study thrombEVAL Selecting antithrombotic therapy for patients with atrial fibrillation.

P2860

Q24197843-B5B985F7-682B-4559-8FA4-AA31E46A5F8B Q26471166-C529B4BC-3C7F-43C2-8446-28E049722BB1 Q26740181-2C682A14-B2E5-4FB4-B61C-1A152B17FBE6 Q26766303-BDDF4E17-8F7C-4103-AC0E-A956C7D8B949 Q26776254-85EA47C2-BB6C-4F4C-B7E4-D45470B2486B Q26782483-FD852BBB-D717-4B0A-A454-8B1AE7C44B11 Q26783457-CC7C035A-9A3D-42DE-9BB3-106C32276181 Q26785480-A8B04091-F31F-4D12-8651-BD526A47DF0C Q26795568-AACD7C7B-9725-42A5-A3B5-2564BE614920 Q26830518-C9CC7CB5-7ED2-4161-A0B0-C7102BA6BA9D Q26851235-26D8E046-7E87-4D50-8612-5150B7ADF7E8 Q26865096-6D179417-EA30-4648-A055-B02D589BF84D Q27024190-50EE7C33-4891-4F57-B7B7-0EC604E10385 Q27025111-FE81010E-3C9E-4051-B74B-F2908631B6AE Q27341873-971B4FD8-789D-4DD6-BEB9-7F2C9296D3EC Q28066141-CA7694E4-3B07-4377-B7C1-C3ADD0B9317B Q28070365-5511D01E-A436-4436-9794-1F841334A446 Q28078177-28E18580-2126-44DD-8113-B72044616DD9 Q28080616-FFB81C0C-2AAE-4655-9B69-61FE73BDD20E Q28315636-8A5511DD-836A-4DFD-B225-DEA7E652E3DC Q30238631-484F6078-832B-4000-B60F-1B44C2CDB437 Q30249817-42000709-7BBB-4F02-9D68-455B1FDD1BF5 Q30389813-2B6F689F-25A4-4085-8D17-1DB1CD0D1BF5 Q30490484-8DC5BD7F-5C44-4D2B-88F8-D507123125CA Q30653045-3AF973ED-4896-4F62-913E-077F899E8ED6 Q31098679-5D74549D-C369-4534-A871-BB803BF51350 Q33164925-4B4B6F35-C30D-4CD7-AE4E-84AA7C8B0D24 Q33585000-AE102DD6-0DF8-44FF-8D9D-5140A9A99D18 Q33653096-4111CBCD-C8A7-4B4C-AA82-42DF458B91E4 Q33698353-9703D8FC-422F-4D64-A3A6-BBA64C1E6529 Q34312531-5A2D8E3E-C856-4864-A7DC-C7D39C043803 Q34469002-3C96F5C9-6F51-45B7-A33C-5C03B7F258ED Q34497581-2A141F91-7A0F-4349-B70B-75CD7EE93125 Q34557287-B50B1F07-63A3-4319-9FB8-BD3769EBDEAC Q34670808-21AEEDA3-07F2-4222-892C-6542C6FBE204 Q34720391-FE696633-E884-4285-8F16-A1E55B052940 Q34725585-D1FFD12E-5A9A-440C-B821-FF2ACA9F9B78 Q35021794-B27C1FA6-AF3E-4130-999D-2AC6BD6FBB4A Q35099559-E4ED8510-A9AE-418F-894A-D90F6D5B9313 Q35650380-A990DC34-4D4A-47A2-99CF-6141940C6C7E

P2860

Dabigatran versus warfarin in patients with mechanical heart valves

http://www.wikidata.org/entity/Q28297637

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Dabigatran versus warfarin in patients with mechanical heart valves

@ast

Dabigatran versus warfarin in patients with mechanical heart valves

@en

Dabigatran versus warfarin in patients with mechanical heart valves

@nl

type

label

Dabigatran versus warfarin in patients with mechanical heart valves

@ast

Dabigatran versus warfarin in patients with mechanical heart valves

@en

Dabigatran versus warfarin in patients with mechanical heart valves

@nl

prefLabel

Dabigatran versus warfarin in patients with mechanical heart valves

@ast

Dabigatran versus warfarin in patients with mechanical heart valves

@en

Dabigatran versus warfarin in patients with mechanical heart valves

@nl

P1433

Q28297637-882F8694-2A7F-40CE-8D72-490F3FD7F2E1

P1476

Q28297637-73A64364-2121-44C5-A556-E51807C7A8E6

P2093

Q28297637-14256F99-9423-4A45-AAC0-934C1F9ECB07

Q28297637-16B9A0E7-0024-40A6-B98C-FBDF380FF60B

Q28297637-5B519B79-1113-425D-BC4F-CD0609E6B025

Q28297637-62CC7205-721D-4AEF-AD2F-83CCE0D0078F

Q28297637-6D4C43AC-C2FA-4072-84FB-DA3CF90774C4

Q28297637-93EDAE90-B2BA-4622-9833-5593B429A6A6

Q28297637-B63031F0-E98C-4EDD-8C04-B982FD1895B0

Q28297637-BD11FDCB-EF10-42AE-BBE8-D9CDD1D31CA7

Q28297637-CC4C3FD8-6412-4454-BBC9-69E3696B966C

Q28297637-ED463D29-803C-4FFB-94DD-D593AC114676

P304

Q28297637-35BAAAF2-CF02-47D6-BC5E-1D04E041A967

P31

Q28297637-19F2D885-8146-4A2B-9599-D753B2308B43

P3181

Q28297637-CA03535A-B760-446D-978D-612E2A9EC5BD

P356

Q28297637-692E0474-CCEF-4006-8AC9-BF57FEF9F5C7

P407

Q28297637-B6E846E8-26A4-4B85-8D3B-97EC7BEB2FA4

P433

Q28297637-4A9133B5-1DE5-43AC-99B7-AEABC719B6E8

P478

Q28297637-3FB6390F-7EC2-4CBF-99E7-76D4197315A8

P50

Q28297637-1B20078C-550D-4785-9D42-08711BBE9E39

Q28297637-3194E375-6D61-4175-B335-3C66B52C679F

Q28297637-38EC7A0E-A582-45C4-8766-66F93325DE48

Q28297637-A777B544-4AFC-4A8B-8515-F03611C0FFCC

Q28297637-AFE54F3B-BFBD-4DC8-B376-7D410044A13C

P577

Q28297637-3EE46C0A-0D7F-4A80-9B2C-9BB7A241B3CF

P698

Q28297637-C595917E-E153-4734-8459-66C3F397FAEF

P3181

P356

P1433

The New England Journal of Medicine

P1476

Dabigatran versus warfarin in patients with mechanical heart valves

@en

P2093

Arie P Kappetein

http://www.w3.org/2001/XMLSchema#string

Hugo Maas

http://www.w3.org/2001/XMLSchema#string

Jeffrey Friedman

http://www.w3.org/2001/XMLSchema#string

Jens-Uwe Voigt

http://www.w3.org/2001/XMLSchema#string

Kelly Guiver

http://www.w3.org/2001/XMLSchema#string

Kevin Devenny

http://www.w3.org/2001/XMLSchema#string

Martina Brueckmann

http://www.w3.org/2001/XMLSchema#string

Maximilian T Lobmeyer

http://www.w3.org/2001/XMLSchema#string

Michael J Mack

http://www.w3.org/2001/XMLSchema#string

Ruth Harper

http://www.w3.org/2001/XMLSchema#string

P304

1206-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1238512

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1300615

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

John W. Eikelboom

Frans Van de Werf

Christopher B. Granger

Maarten L Simoons

P577

2013-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23991661

http://www.w3.org/2001/XMLSchema#string